Maria Arcila, MD / Zofia Piotrowska, MD - New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape

Go online to PeerView.com/CWE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in thoracic oncology and pathology discuss the latest advances in the management of patients with EGFR-mutated NSCLC, including foundational knowledge of oncogenic drivers, such as EGFR mutations, best practice guidance for molecular testing in advanced and early-stage NSCLC, new therapeutic options, and optimal multidisciplinary collaboration to identify actionable targets and individualize treatment to improve outcomes in patients with NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Discuss the latest recommendations and best practices for molecular testing in lung cancer, including the use of tissue- and blood-based testing, for detection of common and less common EGFR mutations in advanced NSCLC as well as the emerging role of EGFR testing in early-stage NSCLC, Describe the established, new, and investigational options for treatment of EGFR-mutated NSCLC, Implement current guidelines, best practices, and multidisciplinary strategies for molecular testing to identify EGFR mutations and other actionable targets and individualize treatment selection throughout the NSCLC disease continuum.